Le Lézard
Classified in: Business, Covid-19 virus
Subject: EARNINGS

IGC Reports Financial Results for Fiscal Year Ended March 31, 2022


India Globalization Capital, Inc. ("IGC" or the "Company") (NYSE American: IGC) announces its financial results for Fiscal Year Ended March 31, 2022.

Highlights for Fiscal 2022:

Revenue was approximately $397 thousand and $898 thousand for Fiscal 2022 and Fiscal 2021, respectively. In Fiscal 2022 and Fiscal 2021, revenue was primarily derived from our Life Sciences segment, which involved sales of in-house brands and alcohol-based hand sanitizers, among others. In Fiscal 2022, we de-emphasized the manufacturing and sale of low margin hand sanitizers and shifted our focus to higher margin white label services and the sale of products under our brands. This increased our gross margin from 12% in Fiscal 2021 to 48% in Fiscal 2022. The infrastructure segment had lower revenue in Fiscal 2022 due to the continued impact of the COVID-19 pandemic.

Selling, general, and administrative ("SG&A") expenses consist primarily of employee-related expenses, sales commission, professional fees, legal fees, marketing, other corporate expenses, allocated general overhead and provisions, depreciation, and write offs relating to doubtful accounts and advances, if any. SG&A expenses increased by approximately $5.3 million or 68% to $13.2 million for Fiscal 2022, from approximately $7.9 million for Fiscal 2021. The increase is attributed to one-time expenses, which include law-suit settlement expenses of approximately $264 thousand; impairment of facility of $833 thousand; net realizable value (NRV) adjustment of $1.7 million for our hemp crop; approximately $475 thousand in provisions for advances paid; approximately $1.7 million in provisions against inventory that was stolen at our vendor's facility; and an increase of approximately $1.3 million attributable to non-cash expenses. Adjusting for approximately $5.3 million in one-time and non-cash expenses, the SG&A for fiscal year 2022 was lower year over year by approximately $500 thousand.

Research and Development ("R&D") expenses were attributed to our Life Sciences segment. The R&D expenses increased by approximately $1.4 million or 151% to $2.3 million in Fiscal 2022, from approximately $929 thousand for Fiscal 2021. The increase is attributed to the now completed Phase 1 clinical trial on Alzheimer's. We expect R&D expenses to increase with progression in Phase 2 trials on IGC-AD1 and pre-clinical trials on TGR-63.

Net loss for Fiscal 2022 was approximately $15 million or $0.30 per share, compared to approximately $8.8 million or $0.21 per share for Fiscal 2021. Adjusting for approximately $5.3 million in one-time and non-cash expenses, the net loss is approximately $9.7 million in Fiscal 2022.

About IGC:

IGC has two segments: Infrastructure and Life Sciences. The company is based in Maryland, U.S.A.

Forward-looking Statements: This press release contains forward-looking statements. These forward-looking statements are based largely on IGC's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the product or formulation described in this release, or failure to obtain regulatory approval for the product or formulation, where required; general economic conditions that are less favorable than expected, including as a result of the ongoing COVID-19 pandemic; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC's SEC filings. IGC incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on June 22, 2022, as if fully incorporated and restated herein. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.

< Financial Tables to Follow>

India Globalization Capital, Inc.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

 

 

 

March 31,
2022
($)

 

 

March 31,
2021
($)

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

 

10,460

 

 

 

14,548

 

Accounts receivable, net

 

 

125

 

 

 

175

 

Inventory

 

 

3,548

 

 

 

5,478

 

Investment in non-marketable securities

 

 

-

 

 

 

80

 

Deposits and advances

 

 

978

 

 

 

3,236

 

Total current assets

 

 

15,111

 

 

 

23,517

 

 

 

 

 

 

 

 

 

 

Intangible assets, net

 

 

917

 

 

 

407

 

Property, plant and equipment, net

 

 

9,419

 

 

 

10,840

 

Non-marketable securities

 

 

-

 

 

 

12

 

Claims and advances

 

 

937

 

 

 

603

 

Operating lease asset

 

 

450

 

 

 

488

 

Total long-term assets

 

 

11,723

 

 

 

12,350

 

Total assets

 

 

26,834

 

 

 

35,867

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

 

981

 

 

 

476

 

Accrued liabilities and others

 

 

1,457

 

 

 

1,588

 

Short-term loans

 

 

3

 

 

 

304

 

Total current liabilities

 

 

2,441

 

 

 

2,368

 

 

 

 

 

 

 

 

 

 

Long-term loans

 

 

144

 

 

 

276

 

Other liabilities

 

 

16

 

 

 

15

 

Operating lease liability

 

 

341

 

 

 

405

 

Total non-current liabilities

 

 

501

 

 

 

696

 

Total liabilities

 

 

2,942

 

 

 

3,064

 

 

 

 

 

 

 

 

 

 

Commitments and Contingencies ? See Note 12

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 par value: authorized 1,000,000 shares, no shares issued or outstanding as of March 31, 2022, or March 31, 2021.

 

 

 

 

 

 

-

 

Common stock and additional paid-in capital, $0.0001 par value: 150,000,000 shares authorized; 51,054,017 and 47,827,273 shares issued and outstanding as of March 31, 2022 and March 31, 2021, respectively.

 

 

116,019

 

 

 

109,720

 

Accumulated other comprehensive loss

 

 

(2,968

)

 

 

(2,774

)

Accumulated deficit

 

 

(89,159

)

 

 

(74,143

)

Total stockholders' equity

 

 

23,892

 

 

 

32,803

 

Total liabilities and stockholders' equity

 

 

26,834

 

 

 

35,867

 

These financial statements should be read in connection with the accompanying notes on Form 10-K for fiscal year ending March 31, 2022, filed with the SEC on June 22, 2022.

India Globalization Capital, Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except loss per share and share data)

 

 

Years Ended March 31,

 

 

 

2022
($)

 

 

2021
($)

 

Revenue

 

 

397

 

 

 

898

 

Cost of revenue

 

 

(203

)

 

 

(785

)

Gross profit

 

 

194

 

 

 

113

 

Selling, general and administrative expenses

 

 

(13,292

)

 

 

(7,908

)

Research and development expenses

 

 

(2,330

)

 

 

(929

)

Operating loss

 

 

(15,428

)

 

 

(8,724

)

Impairment of investment

 

 

(49

)

 

 

(169

)

Other income, net

 

 

461

 

 

 

82

 

Loss before income taxes

 

 

(15,016

)

 

 

(8,811

)

Income tax expense/benefit

 

 

-

 

 

 

-

 

Net loss attributable to common stockholders

 

 

(15,016

)

 

 

(8,811

)

Foreign currency translation adjustments

 

 

(194

)

 

 

76

 

Comprehensive loss

 

 

(15,210

)

 

 

(8,735

)

 

 

 

 

 

 

 

 

 

Loss per share attributable to common stockholders:

 

 

 

 

 

 

 

 

Basic & diluted

 

$

(0.30

)

 

$

(0.21

)

Weighted-average number of shares used in computing loss per share amounts:

 

 

49,991,631

 

 

 

41,963,382

 

These financial statements should be read in connection with the accompanying notes on Form 10-K for fiscal year ending March 31, 2022, filed with the SEC on June 22, 2022.


These press releases may also interest you

at 18:23
Novavax, Inc. , a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Novavax...

at 18:10
VR Resources Ltd. , the (Company), or (VR), announces a non-brokered private placement ("Financing") for gross proceeds of up to $4,000,000. The financing is a hard-dollar private placement, non-brokered, on a best efforts basis. It will...

at 17:50
Lowell Farms Inc. (the "Company") , a California-born innovator in cannabis cultivation and maker of the legendary brand Lowell Smokes, along with its subsidiary, Indus Holding Company ("Subco"), has issued an aggregate of $4.2 million of senior...

at 17:30
Akili, a leading digital medicine company, today completed its previously announced business combination with Social Capital Suvretta Holdings Corp. I ("SCS") , a publicly traded special purpose acquisition company. The newly formed company, Akili,...

at 17:25
Pender Growth Fund Inc. (the "Company") today announced its financial and operational results for the three months and six months ended June 30, 2022. Financial Highlights (Unaudited) Net loss was $58,521,457 for the three months ended June 30,...

at 16:43
Today, the Honourable Harjit S. Sajjan, Minister of International Development and Minister responsible for the Pacific Economic Development Agency of Canada, on behalf of the Honourable Dominic LeBlanc, Minister of Intergovernmental Affairs,...



News published on 22 june 2022 at 23:30 and distributed by: